Shares of Pacira BioSciences Inc (PCRX) traded 19% higher on Tuesday morning, following upward price target revisions by ...

Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a ...

Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement ...

Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...

Truist analyst Les Sulewski raised the firm’s price target on Pacira (PCRX) to $28 from $25 and keeps a Hold rating on the ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a ...

The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044 expiration date of the last-to-expire of Pacira’s Orange Book-listed patents for Exparel.

The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044 expiration date of the last-to-expire of Pacira’s Orange Book-listed patents for EXPAREL.